ArticleFrontiers in oncology2019

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.

Chang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.